TransThera Biosciences Co., Ltd Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Nanjing China (2016)

Organization Overview

First Clinical Trial
2018
NCT03654547
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

TransThera Biosciences Co., Ltd | TransThera Sciences (Nanjing), Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Tinengotinib (7 trials)

Drugs in Phase 2 Trials (2)

atezolizumab (Tecentriq) (1 trial)

paclitaxel (taxol) (2 trials)

Drugs in Phase 1 Trials (4)

tt-00434 (1 trial)

tt-00920 (3 trials)

tt-00973 (1 trial)

tt-01488 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Heart Failure (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 7